Publication:
Homologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications

Simple item page
dc.contributor.coauthorShash, E.
dc.contributor.coauthorVardar, M.A.
dc.contributor.coauthorBoujassoum, S.
dc.contributor.coauthorRiromar, J.
dc.contributor.coauthorAboutaleb, A.
dc.contributor.coauthorSadek, F.
dc.contributor.coauthorSamy, E.
dc.contributor.coauthorBahaj, W.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorTaşkıran, Çağatay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-07-02T07:03:08Z
dc.date.available2026-03-27
dc.date.issued2026
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis study was supported by AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who are co-developing olaparib.
dc.description.versionPublished version
dc.identifier.WoSQuartileQ2
dc.identifier.doi10.1186/s12885-025-15537-3
dc.identifier.eissn1471-2407
dc.identifier.embargoNo
dc.identifier.issue1
dc.identifier.pubmed41639797
dc.identifier.scopus2-s2.0-105030821753
dc.identifier.urihttps://doi.org/10.1186/s12885-025-15537-3
dc.identifier.urihttps://hdl.handle.net/20.500.14288/32833
dc.identifier.volume26
dc.identifier.wos001698175000001
dc.keywordsBRCA mutations
dc.keywordsGenomic instability
dc.keywordsHomologous recombination deficiency
dc.keywordsMiddle East
dc.keywordsOvarian cancers
dc.languageeng
dc.publisherBioMed Central
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofBMC Cancer
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectOncology
dc.titleHomologous recombination deficiency in newly diagnosed advanced ovarian cancer across nine Middle East countries: prevalence, real-world testing pathways, and treatment implications
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext